Welcome to our dedicated page for Else Nutrition H news (Ticker: BABYF), a resource for investors and traders seeking the latest updates and insights on Else Nutrition H stock.
Else Nutrition Holdings Inc. reports developments tied to its plant-based nutrition business for infants, toddlers, children, and adults. The company’s updates center on whole-food, non-soy, non-dairy products, including toddler nutrition and baby cereal lines made with ingredients such as almonds, buckwheat, and tapioca.
Recurring news themes include U.S. infant-formula regulatory activity, FDA guidance on protein standards, product pipeline positioning, sales milestones, operating and financial progress, shareholder meeting results, governance matters, and capital-structure actions related to convertible funding agreements and equity issuance approvals.
Else Nutrition (OTCQX:BABYF) confirmed its common share consolidation and upcoming post-consolidation trading. The company completed a 1-for-10 share consolidation on July 7, 2026. Its shares will begin trading on a post-consolidation basis on the CSE under symbol BABY at market open on July 9, 2026. The corrected new CUSIP is 290257609 and ISIN is CA2902576099.
Else Nutrition (CSE:BABY, OTCQX:BABYF) completed a 1‑for‑10 share consolidation. Post‑consolidation, issued and outstanding shares decreased from 61,926,043 to approximately 6,192,604, effective for CSE trading on July 8, 2026.
The company also settled $207,100 of debt with 1,380,667 shares at $0.15, issued a US$372,000 convertible security with 1,600,413 warrants, and will issue 628,704 shares from US$70,500 in conversions.
Else Nutrition (OTCQX:BABYF) received conditional approval to list its common shares on the Canadian Securities Exchange (CSE). The listing remains subject to CSE approval and customary conditions, with no assurance it will be obtained.
The company plans US$310,000 in additional funding with Lind Global Fund III LP, a 10-for-1 share consolidation, and settlement of $207,000 of debt via common shares at a post-consolidated price of $0.15 per share. Else Nutrition is targeting July 7 for trading commencement on the CSE, conditional on final filings, financing, debt settlement and consolidation.
Else Nutrition (OTCQX:BABYF) is launching a manufacturing drive in Q2 2026 to address strong demand in the US and Canada. The company previously faced cash constraints and product shortages that hurt revenue. The new plan aims to keep products in stock through summer 2026 and secure inventory for the remainder of the year, supporting renewed growth, a Canadian relaunch, and long-term profitability goals.
Else Nutrition (OTCQX:BABYF) reported Q1 2026 results, with revenue of $1.5 million versus $2.1 million a year ago, mainly due to out-of-stock issues.
Gross margin rose to 40% from 24%, quarterly net loss declined to about $0.6 million from $3.4 million, and operating expenses fell 45% to $1.2 million. Cash balance on March 31, 2026 was $245 thousand, including restricted cash. Management highlighted ongoing work with the FDA on infant formula commercialization and parallel efforts to secure a listing on the Canadian Securities Exchange while addressing TSX delisting challenges.
Else Nutrition (OTCQX: BABYF) applauded the Trump Administration's FY2027 budget request, which proposes an approximately $108.5 million increase to FDA Human Foods Program funding versus FY2026 to support infant formula modernization. Else highlighted FDA priority listing for infant formula and an expected 2026 final Protein Efficiency Ratio (PER) guidance as potential catalysts for plant-based, non-soy, non-dairy formula innovation.
Else said these regulatory shifts and initiatives like Operation Stork Speed could expand FDA resources, clinical validation pathways, and pathway clarity for next-generation formulations while the company monitors developments.
Else Nutrition (OTCQX: BABYF) said the FDA has listed Protein Efficiency Ratio (PER) Rat Bioassay Study Guidance as an active topic in its Foods Program on March 10, 2026. Else states this advances scientific expectations for protein quality in novel infant formulas and may reduce regulatory uncertainty for plant‑based formulas.
The company highlights alignment with federal modernization efforts including Operation Stork Speed and says clearer guidance could accelerate U.S. commercialization potential for its plant‑based infant formula.
Else Nutrition (OTC: BABYF) announced it has surpassed one million cans sold across its toddler and kids powder product lines as of Jan 29, 2026. The milestone is presented as evidence of accelerating consumer demand for clean, non-dairy, non-soy, gluten-free childhood nutrition.
The company highlights thousands of parent testimonials reporting improvements in GI sensitivities, CMPA, eczema and feeding issues, and says it is advancing U.S. regulatory efforts for plant-based infant formula under Operation Stock Speed.
Else Nutrition Holdings (OTCQX: BABYF, TSX: BABY) reported results from its annual general meeting held December 29, 2025. Shareholders representing 6,473,877 shares (17.30%) of issued and outstanding shares attended.
Shareholders approved setting the board size at five directors and re-elected all management nominees with individual "for" votes ranging from 97.56% to 99.17%. The meeting also approved re-appointing Kost Forer Gabbay & Kassierer (Ernst & Young member firm) as auditor, the issuance of common shares to Lind Global Fund II, LP and Lind Global Fund III, LP under existing convertible security agreements, and the continuation of the company’s stock option plan. Voting details are available on the company’s SEDAR+ profile.
Else Nutrition (OTC: BABYF / TSX: BABY) appointed Natie Zilberberg as Chief Financial Officer and Corporate Secretary effective January 5, 2026, replacing Shay Shamir. Mr. Zilberberg has 10+ years of finance experience at VC-backed firms across fintech, agrotech, and renewable energy and previously served as CFO of Tomgrow and Financial Controller at Salaryo. His background includes leading strategic financial planning, securing credit facilities, shortening reporting cycles, supporting equity and debt raises, and executing a $30 million acquisition.